Prevalence and clinical association with calcinosis cutis in early systemic sclerosis

2021 ◽  
pp. 1-11
Author(s):  
Chawiporn Muktabhant ◽  
Punthip Thammaroj ◽  
Prathana Chowchuen ◽  
Chingching Foocharoen
Author(s):  
David Roofeh ◽  
Celia J F Lin ◽  
Jonathan Goldin ◽  
Grace Hyun Kim ◽  
Daniel E Furst ◽  
...  

Rheumatology ◽  
2010 ◽  
Vol 50 (2) ◽  
pp. 317-323 ◽  
Author(s):  
G. Valentini ◽  
G. Cuomo ◽  
G. Abignano ◽  
A. Petrillo ◽  
S. Vettori ◽  
...  

2021 ◽  
pp. 239719832110043
Author(s):  
Miguel Angel Garcés Villalá ◽  
Carolina Zorrilla Albert

Introduction: Limited cutaneous systemic sclerosis with special manifestations (calcinosis cutis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) is part of the group of connective tissue diseases, these rare autoimmune systemic pathologies cause thickening and hardening of tissues in different parts of the body and can lead to complex disorders. Oral manifestations of systemic sclerosis may include limited ability to open the mouth, xerostomia, periodontal disease, enlarged periodontal ligament, and bone resorption of the jaw. Case Description: A 54-year-old Caucasian patient presented with oral pain, swallowing, phonation and chewing difficulties associated with dental instability, hygiene/handling difficulties and her main problem with microstomia, which prevented her from removing the skeletal prosthesis for 4 years, depriving her of social life. Gradual treatment with dental implants was diagnosed and planned to support a fixed total denture adapted to the ridge with self-cleaning characteristics. After implant insertion, panoramic radiographs with standardized parameters were taken to compare crestal bone levels at the time of prosthesis placement and with 10 years of follow-up. Conclusion: The average crestal bone loss of the 12 implants after the 10 years of follow-up was 1.26 mm for the maxilla and 1.17 mm for the mandible. The survival of the 12 support implants of two total fixed prostheses in a clinical/radiographic follow-up of 10 years was 100%. After 10 years of follow-up, the 12 implants inserted had a bone loss similar to that of healthy patients and no pathologies were registered, recovering function, aesthetics, and self-esteem. This therapy must be implemented before the interincisal distance decreases to 30 mm to allow intraoral surgical/prosthetic access. Implant-supported total fixed rehabilitation is a viable, predictable, and recommended therapy in patients with limited cutaneous systemic sclerosis.


2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 398.2-398
Author(s):  
J. Sanchez ◽  
S. Jordan ◽  
J. Distler ◽  
B. Maurer ◽  
D. Huscher ◽  
...  

Antibodies ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 12
Author(s):  
Roberto Lande ◽  
Raffaella Palazzo ◽  
Anna Mennella ◽  
Immacolata Pietraforte ◽  
Marius Cadar ◽  
...  

Chemokine (C-X-C motif) ligand 4 (CXCL4) is a biomarker of unfavorable prognosis in Systemic Sclerosis (SSc), a potentially severe autoimmune condition, characterized by vasculitis, fibrosis and interferon (IFN)-I-signature. We recently reported that autoantibodies to CXCL4 circulate in SSc patients and correlate with IFN-α. Here, we used shorter versions of CXCL4 and CXCL4-L1, the CXCL4 non-allelic variant, to search for autoantibodies exclusively reacting to one or the other CXCL4 form. Moreover, to address whether anti-CXCL4/CXCL4-L1 antibodies were present before SSc onset and predicted SSc-progression, we longitudinally studied two VEDOSS (Very Early Diagnosis of Systemic Sclerosis) patient cohorts, separating SSc-progressors from SSc-non-progressors. We found that anti-CXCL4-specific autoantibodies were present in both SSc and VEDOSS patients (both SSc-progressors and SSc-non-progressors). Anti-CXCL4-L1-specific autoantibodies were especially detected in long-standing SSc (lsSSc). Anti-CXCL4/CXCL4-L1 antibodies correlated with IFN-α and with specific SSc-skin features but only in lsSSc and not in early SSc (eaSSc) or VEDOSS. Thus, a broader antibody response, with reactivity spreading to CXCL4-L1, is characteristic of lsSSc. The early anti-CXCL4 autoantibody response seems qualitatively different from, and likely less pathogenic than, that observed in advanced SSc. Lastly, we confirm that anti-CXCL4 autoantibodies are SSc-biomarkers and uncover that also CXCL4-L1 becomes an autoantigen in lsSSc.


2012 ◽  
Vol 14 (4) ◽  
pp. R188 ◽  
Author(s):  
Gabriele Valentini ◽  
Serena Vettori ◽  
Giovanna Cuomo ◽  
Michele Iudici ◽  
Virginia D'Abrosca ◽  
...  

2016 ◽  
Vol 27 (4) ◽  
pp. 614-617 ◽  
Author(s):  
Yuka Ikawa ◽  
Yasuhito Hamaguchi ◽  
Naoki Mugii ◽  
Takashi Matsushita ◽  
Kazuhiko Takehara

2020 ◽  
Vol 12 (6) ◽  
pp. 127-128
Author(s):  
Susana Rodrigues ◽  
Catrine Ferreira ◽  
Tiago Coelho ◽  
Diogo Gaspar ◽  
Jean Fallah ◽  
...  

Calcinosis cutis is a rare disorder characterized by of deposition of insoluble calcium salts in the skin and subcutaneous tissue. Five subtypes of calcinosis cutis are described: dystrophic, metastatic, idiopathic, iatrogenic, and calciphylaxis.1 Of these subtypes, dystrophic calcinosis (DC) is the most common, and it is the most frequently seen in association with underlying autoimmune connective tissue diseases.2 Dermatomyositis, systemic sclerosis and less commonly systemic lupus erythematous were described to be complicated by DC. However, DC associated with rheumatoid arthritis (RA) is extremely rare.2 The condition causes substantial morbidity and is associated with pain and limitation of movement when the process involves areas close to joints or when ulceration occurs.2 We report a middle age Sudanese woman with good controlled RA who developed dystrophic calcinosis cutis.


Sign in / Sign up

Export Citation Format

Share Document